Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5):646-74; PMID:21376230; https://doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutant 2003; 21(3):217-28; PMID:12619107; https://doi.org/10.1002/humu.10179
   PubMed Web of Science ®Google Scholar
• Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22(20):3092-8; PMID:12789286; https://doi.org/10.1038/sj.onc.1206461
   PubMed Web of Science ®Google Scholar
• Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992; 89(21):10557-61; PMID:1438246; https://doi.org/10.1073/pnas.89.21.10557
   PubMed Web of Science ®Google Scholar
• Coleman A, Fountain JW, Nobori T, Olopade OI, Robertson G, Housman DE, Lugo TG. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 1994; 54(2):344-8; PMID:8275465; www.cancerres.aacrjournals.org/content/54/2/344.long
   PubMed Web of Science ®Google Scholar
• Merkel CA, Medrano RF, Barauna VG, Strauss BE. Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Ther 2013; 20(5):317-25; PMID:23618951; https://doi.org/10.1038/cgt.2013.23
   PubMed Web of Science ®Google Scholar
• Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 2011; 71(18):5998-6009; PMID:21764762; https://doi.org/10.1158/0008-5472.CAN-10-3211
   PubMed Web of Science ®Google Scholar
• Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000; 14(18):2358-65; PMID:10995391; https://doi.org/10.1101/gad.827300
   PubMed Web of Science ®Google Scholar
• Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56:727-77; PMID:2441659; https://doi.org/10.1146/annurev.biochem.56.1.727 10.1146/annurev.bi.56.070187.003455
   PubMed Web of Science ®Google Scholar
• Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ. Interferome v2.0: An updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013; 41(Database issue):D1040-6; PMID:23203888; https://doi.org/10.1093/nar/gks1215
   PubMed Web of Science ®Google Scholar
• González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12(2):125-35; PMID:22222875; https://doi.org/10.1038/nri3133
   PubMed Web of Science ®Google Scholar
• Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424(6948):516-23; PMID:12872134; https://doi.org/10.1038/nature01850
   PubMed Web of Science ®Google Scholar
• Zhu Z, Yang Y, Wei J, Shao D, Shi Z, Li B, Liu K, Qiu Y, Zheng H, Ma Z. Type I interferon-mediated immune response against influenza A virus is attenuated in the absence of p53. Biochem Biophys Res Commun 2014; 454(1):189-95; PMID:25450379; https://doi.org/10.1016/j.bbrc.2014.10.067
   PubMed Web of Science ®Google Scholar
• Hu G, Mancl ME, Barnes BJ. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res 2005; 65(16):7403-12; PMID:16103093; https://doi.org/10.1158/0008-5472.CAN-05-0583
   PubMed Web of Science ®Google Scholar
• Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002; 21(18):2914-8; PMID:11973653; https://doi.org/10.1038/sj.onc.1205459
   PubMed Web of Science ®Google Scholar
• Sandoval R, Xue J, Pilkinton M, Salvi D, Kiyokawa H, Colamonici OR. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J Biol Chem 2004; 279(31):32275-80; PMID:15169789; https://doi.org/10.1074/jbc.M313830200
   PubMed Web of Science ®Google Scholar
• Bajgelman MC, Strauss BE. Development of an adenoviral vector with robust expression driven by p53. Virology 2008; 371(1):8-13; PMID:18076963; https://doi.org/10.1016/j.virol.2007.11.015
   PubMed Web of Science ®Google Scholar
• Tamura RE, da Silva Soares RB, Costanzi-Strauss E, Strauss BE. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy. Cancer Biol Ther 2016; 17(12):1221-30; PMID:27646031; https://doi.org/10.1080/15384047.2016.1235655
   PubMed Web of Science ®Google Scholar
• Merkel CA, da Silva Soares RB, de Carvalho AC, Zanatta DB, Bajgelman MC, Fratini P, Costanzi-Strauss E, Strauss BE. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer 2010; 10:316; PMID:20569441; https://doi.org/10.1186/1471-2407-10-316
   PubMed Web of Science ®Google Scholar
• Medrano RF, Catani JP, Ribeiro AH, Tomaz SL, Merkel CA, Costanzi-Strauss E, Strauss BE. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: A novel combination for cancer immunotherapy. Cancer Immunol Immunother 2016; 65(4):371-82; PMID:26887933; https://doi.org/10.1007/s00262-016-1807-8
   PubMed Web of Science ®Google Scholar
• Keil D, Luebke RW, Pruett SB. Quantifying the relationship between multiple immunological parameters and host resistance: Probing the limits of reductionism. J Immunol 2001; 167(8):4543-52; PMID:11591782; https://doi.org/10.4049/jimmunol.167.8.4543
   PubMed Web of Science ®Google Scholar
• Catani JP, Medrano RF, Hunger A, Del Valle P, Adjemian S, Zanatta DB, Kroemer G, Costanzi-Strauss E, Strauss BE. Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma. Transl Oncol 2016; 9(6):565-74; PMID:27916291; https://doi.org/10.1016/j.tranon.2016.09.011
   PubMed Web of Science ®Google Scholar
• Hunger A, Medrano RF, Zanatta DB, Del Valle PR, Merkel CA, Salles TA, Ferrari DG, Furuya TK, Bustos SO, de Freitas Saito R et al. Reestablishment of p53/Arf and interferon-β pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. Cell Death Discov 2017; 3:17017; PMID:28386458; https://doi.org/10.1038/cddiscovery.2017.17
   PubMedGoogle Scholar
• Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology 2016; 5(6):e1149673; PMID:27471616; https://doi.org/10.1080/2162402X.2016.1149673
   PubMed Web of Science ®Google Scholar
• Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11(8):519-31; PMID:21785456; https://doi.org/10.1038/nri3024
   PubMed Web of Science ®Google Scholar
• Shaabani N, Duhan V, Khairnar V, Gassa A, Ferrer-Tur R, Häussinger D, Recher M, Zelinskyy G, Liu J, Dittmer U et al. CD169(+) macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection. Cell Death Dis 2016; 7(11):e2446; PMID:27809306; https://doi.org/10.1038/cddis.2016.350
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017; 17(2):97-111; PMID:27748397; https://doi.org/10.1038/nri.2016.107
   PubMed Web of Science ®Google Scholar
• Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N, Van Gool SW. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015; 136(5):E313-25; PMID:25208916; https://doi.org/10.1002/ijc.29202
   PubMed Web of Science ®Google Scholar
• Pampena MB, Levy EM. Natural killer cells as helper cells in dendritic cell cancer vaccines. Front Immunol 2015; 6:13; PMID:25674087; https://doi.org/10.3389/fimmu.2015.00013
   PubMed Web of Science ®Google Scholar
• Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med 2016; 8(328):328ra27; PMID:26936504; https://doi.org/10.1126/scitranslmed.aae0105
   PubMed Web of Science ®Google Scholar